ARIES-3: Ambrisentan Therapy in a Diverse Population of Patients with Pulmonary Hypertension

Cardiovascular Therapeutics

Volumn 30, Issue 2, 2012, Pages 93-99

  Badesch, David B ^a   Feldman, Jeremy ^b   Keogh, Anne ^c   Mathier, Michael A ^d   Oudiz, Ronald J ^e   Shapiro, Shelley ^f   Farber, Harrison W ^g   McGoon, Michael ^h   Frost, Adaani ⁱ   Allard, Martine ^j   Despain, Darrin ^j   Dufton, Christopher ^j   Rubin, Lewis J ^k  

^a UNIVERSITY OF COLORADO   (United States)

^b Arizona Pulmonary Specialists Ltd   (United States)

^c ST VINCENT S HOSPITAL   (Australia)

^d UNIVERSITY OF PITTSBURGH   (United States)

^e UCLA MEDICAL CENTER   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h MAYO CLINIC   (United States)

ⁱ BAYLOR COLLEGE OF MEDICINE   (United States)

^j GILEAD SCIENCES   (United States)

^k UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

Ambrisentan; Non Group 1 patient population; Prostacyclin analog therapy; Pulmonary hypertension; Sildenafil therapy

Indexed keywords

AMBRISENTAN; BRAIN NATRIURETIC PEPTIDE;

ADULT; ARTHRALGIA; ARTICLE; BACKACHE; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; COUGHING; DEPRESSION; DIARRHEA; DIZZINESS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; EPISTAXIS; EXERCISE; FATIGUE; FEMALE; FLUSHING; HEADACHE; HEART RIGHT VENTRICLE FAILURE; HUMAN; HYPOKALEMIA; HYPOXEMIA; INSOMNIA; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; NAUSEA; NOSE CONGESTION; PAIN; PERIPHERAL EDEMA; PNEUMONIA; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SIDE EFFECT; THORAX PAIN; THROMBOEMBOLISM; TREATMENT DURATION; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VOMITING; WALKING;

ADULT; AGED; DOUBLE-BLIND METHOD; EXERCISE TOLERANCE; FEMALE; HUMANS; HYPERTENSION, PULMONARY; LONG-TERM CARE; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PHENYLPROPIONATES; PYRIDAZINES; RECEPTOR, ENDOTHELIN A; SURVIVAL; TREATMENT OUTCOME; WALKING;

EID: 84858279164     PISSN: 17555914     EISSN: 17555922     Source Type: Journal    
DOI: 10.1111/j.1755-5922.2011.00279.x     Document Type: Article

References (21)

1. Simonneau G, Galie N, Rubin LJ, Langleben D, Seeger W, Domenighetti G. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004;43(12 Suppl S):5S-12S.
2. Rubin LJ. Primary pulmonary hypertension. Chest 1993;104:236-250.
3. Badesch DB, Abman SH, Simmoneau G, Rubin LJ, McLaughlin V. Medical therapy for pulmonary arterial hypertension: Updated ACCP evidence-based clinical practice guidelines. Chest 2007;131:1917-1928.
4. Morrell NW, Adnot S, Archer SL, Dupuis J, Jones PL, MacLean MR. Cellular and molecular basis of pulmonary arterial hypertension. J Am Coll Cardiol 2009;54:S20-S31.
5. Peacock A, Simonneau, Rubin L. Controversies, uncertainties and future research on the treatment of chronic thromboembolic pulmonary hypertension. Proc Am Thorac Soc 2006;3:608-614.
6. Shorr AF, Helman DL, Davies DB, Nathan SD. Pulmonary hypertension in advanced sarcoidosis: Epidemiology and clinical characteristics. Eur Respir J 2005;25:783-788.
7. Rodriguez-Roisin R, MacNee W. Pathophysiology of chronic obstructive pulmonary disease. Eur Respir Mon 1998;3:107-126.
8. Polomis D, Runo JR, Meyer KC. Pulmonary hypertension in interstitial lung disease. Curr Opin Pulm Med 2008; 14:462-469.
9. Shorr AF, Wainright JL, Cors CS, Lettieri CJ, Nathan SD. Pulmonary hypertension in patient with pulmonary fibrosis awaiting lung transplant. Eur Respir J 2007;30:715-721.
10. Lettieri CJ, Nathan SD, Barnett SD, Ahmad S, Shorr AF. Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest 2006;129:746-752.
11. Nadrous HF, Pellikka PA, Krowka MJ, Swanson KL, Chaowalit N, Decker PA. Pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Chest 2005;128:2393-2399.
12. Channick RN, Sitbon O, Barst RJ, Manes A, Rubin LJ. Endothelin receptor antagonists in pulmonary arterial hypertension. J Am Coll Cardiol 2004;43(12 Suppl S):S62-S67.
13. Barst RJ. A review of pulmonary arterial hypertension: Role of ambrisentan. Vasc Health Risk Manag 2007;3:11-22.
14. Galie N, Olschewski H, Oudiz RJ, Torres F, Frost A, Ghofrani HA. Ambrisentan for the treatment of pulmonary arterial hypertension: Results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 2008;117:3010-3020.
15. Guyatt GH, Sullivan MJ, Thompson PJ, Fallen EL, Pugsley SO, Taylor DW. The 6-minute walk: A new measure of exercise capacity in patients with chronic failure. CMAJ 1985;132:919-923.
16. Hahn GJ, Meeker WQ. Statistical intervals: A guide for practitioners. New York, NY: John Wiley & Sons, 1991;1-387.
17. McLaughlin VV, Presberg KW, Doyle RL, Abman SH, McCrory DC, Fortin T. Prognosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004;126:S78-S92.
18. Galie N, Badesch D, Oudiz R, Simonneau G, McGoon MD, Keogh AM. Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2005;46:529-535.
19. McLaughlin V. Long-term ambrisentan therapy for pulmonary arterial hypertension in patients who previously received placebo in ARIES-1 or ARIES-2 [abstract]. Am J Respir Crit Care Med 2008;177:A697.
20. Rubin LJ, Badesch DB, Barst RJ, et al.; for the Bosentan Randomized Trial of Endothelin Antagonist Therapy Study Group. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346:896-903.
21. Galie N, Rubin LJ, Hoeper M, Jansa P, Al-Hiti H, Meyer GMB. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): A double-blind, randomized controlled trial. Lancet 2008;371:2093-2100.